AnGes, Inc. has acquired EmendoBio, Inc.
Lincoln International is pleased to have advised AnGes, Inc., a Tokyo Stock Exchange-listed $1.6 billion market capitalization commercial stage Japanese biopharmaceutical company focused on gene-based medicines, on its acquisition of EmendoBio, Inc., a leader in next-generation novel nuclease discovery and gene editing technologies, at a valuation of $250 million.
Headquartered in the United States with research and development activities mainly conducted in Israel, EmendoBio is a next generation CRISPR gene editing company that leverages dual proprietary technology platforms to enable high precision gene editing throughout the genome. EmendoBio’s novel nuclease discovery platform broadens the targetable range of the genome, while its target-specific optimization platform enables highly precise editing, including allele specific editing while maintaining high efficiencies. The capabilities of the OMNI technology platforms along with deep expertise in genomic medicine, protein engineering and therapeutic development, provide EmendoBio with a unique advantage when addressing indications within hematology, oncology, ophthalmology and other disease areas.
Dr. Ei Yamada, President and Chief Executive Officer of AnGes, stated, “The acquisition of EmendoBio represents a key step in the AnGes strategy to focus on innovative medicines for diseases with high unmet medical needs by identifying unique combinations of genetic medicines and therapeutic modalities based on cutting-edge science. The transaction positions AnGes to expand its pipeline and partnerships and introduce gene editing capabilities by leveraging EmendoBio’s proprietary platforms, team of seasoned scientists and researchers and valued relationships with academic collaborators and scientific advisors.”
Lincoln International acted as exclusive financial advisor to AnGes on this transaction.
I am grateful to the Lincoln team for providing valuable advice and detail-oriented support throughout the critical phases of this transaction.
Meet our Senior Team
View More Transactions
Lincoln International advised Olive AI on the sale of substantially all of its assets to Waystar and Humata Health
Lincoln International advised Scantox Group, a portfolio company of Impilo, on its acquisition of QPS Austria’s Neuropharmacology Division
Lincoln International advised Wind Point Partners on the acquisition of Central Moloney Incorporated
Lincoln International has advised EMZ Partners on the sale of ASSEPRO to The Ardonagh Group
Lincoln International advised LEBC Holdings on its agreement to sell Aspira Corporate Solutions to Titan Wealth
Lincoln International advised Scheybeeck on the sale of a majority stake in BUKO Traffic & Safety to Equistone
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.